Abstract:Summary Statement Combination of sorafenib with irradiation achieved synergistic effect with dose reduction in both 143B and HOS cell lines. This demonstrated the potential application of sorafenib in the treatment of osteosarcoma metastasis and radiation resistance. Introduction More than 20% of patients with osteosarcoma die of the disease within 5 years due to tumour relapse and metastasis. Identifying new treatment that works singly or in combination with conventional therapies is urgently required. We previously found that the Ras/Raf/MAPK pathway was associated with lung metastasis in a 143B inoculated osteosarcoma orthotopic mouse model 1 . Sorafenib, a multi-kinase inhibitor, has shown potent anticancer effect including in osteosarcoma 2 through the inhibition of Raf-1 and other targets 3 . The aims of this study were to investigate effect of sorafenib on osteosarcoma cell lines with or without activated Ras/Raf/MAPK signalling and to decide whether sorafenib could enhance irradiation on these cells. Materials and Methods Osteosarcoma cell lines 143B (HOS with Ras gene transfection), HOS and U2OS were used. Clonogenic assay was applied for assessing tumour growth and colony formation with or without treatment. Sorefenib was provided by Bayer gratis. Irradiation was performed using the Therapax DXT300 Orthovoltage Radiation System (Pantak, Connecticut, USA). Three doses of sorafenib (1, 2, 4 ug/ml) and three doses of radiation (50, 100, 200 cGy) were used with vehicle controls. In the combination therapy sorafenib was given at pre-, concurrent and post-irradiation. Each treatment was duplicated with the experiment being repeated once. Results Sorafenib monotherapy achieved 50% inhibition (EC50) effects in all three tested cell lines with 7.05 ug/ml for 143B, 1.59 for HOS and 2.41 for U2OS. The 143B cell line was seriously resistant to irradiation with EC50 of 167 Gy, whilst other cell lines were relatively sensitive (HOS, 1.5 Gy and U2OS, 1.0 Gy). Combination of sorafenib with irradiation achieved synergistic effect with dose reduction in both 143B and HOS cell lines, but no obvious effect in U2OS cells. Discussion Sorafenib demonstrated inhibitory effects on cell growth and colony formation even in a Ras/Raf/MAPK signalling activated osteosarcoma cell line, suggesting its potential application in the treatment of some metastatic osteosarcoma. Activated Ras/Raf/MAPK signalling is one of the mechanisms of radiation resistance and the synergistic effect of soratenib with irradiation combination therapy in this cell population indicated it9s potential application in the treatment of irradiation resistant osteosarcoma. The dose reduction achieved by this combination could benefit patients with less specific side effects.

VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment

The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib

Phosphorylated ERK is a Potential Prognostic Biomarker for Sorafenib Response in Hepatocellular Carcinoma.

AZD6244 (ARRY-142886) Enhances the Therapeutic Efficacy of Sorafenib in Mouse Models of Gastric Cancer.

Synergistic Growth Inhibition by Sorafenib and Cisplatin in Human Osteosarcoma Cells

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.

Sorafenib Inhibits Doxorubicin-Induced PD-L1 Upregulation to Improve Immunosuppressive Microenvironment in Osteosarcoma

Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.

VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways

An Investigation of the Effect of Sorafenib on Tumour Growth and Recurrence after Liver Cancer Resection in Nude Mice Independent of Phosphorylated Extracellular Signal-Regulated Kinase Levels

SORAFENIB MONOTHERAPY AND COMBINATION THERAPY WITH IRRADIATION IN OSTEOSARCOMA CELL LINES

Effect of dual properties of regorafenib in osteosarcoma on tumor progression and bone parameters in mouse preclinical models.

Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway

Targeting nerve growth factor-mediated osteosarcoma metastasis: mechanistic insights and therapeutic opportunities using larotrectinib

VEGF-siRNA Silencing Induces Apoptosis, Inhibits Proliferation and Suppresses Vasculogenic Mimicry in Osteosarcoma in Vitro.

ZD6474, a New Treatment Strategy for Human Osteosarcoma, and Its Potential Synergistic Effect with Celecoxib

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

Coordinative Activities of STAT3 Inhibitor BP-1-102 and Sorafenib Against Proliferation, Angiogenesis and EMT in Hepatocellular Carcinoma

Sorafenib Inhibited Cell Growth Through the MEK/ERK Signaling Pathway in Acute Promyelocytic Leukemia Cells

Inhibitory Effects of VEGF-siRNA Mediated by Adenovirus on Osteosarcoma-Bearing Nude Mice

Dual Mechanism of Action of Resveratrol in Notch Signaling Pathway Activation in Osteosarcoma